The study was small — just 48 adults — and lasted just over two months, so it’s not the final word. But the results add to evidence that GLP-1 drugs like Ozempic might help with cravings for things ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Chronic pain is a worldwide epidemic that disproportionately affects women. These surgeons have found innovative solutions - ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...